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Comparison of Protein Active Site Structures
for Functional Annotation of Proteins and Drug Design
Robert Powers, Jennifer C. Copeland, Katherine Germer, Kelly A. Mercier
Department of Chemistry, University of Nebraska–Lincoln

Viswanathan Ramanathan and Peter Revesz
Department of Computer Science and Engineering, University of Nebraska-Lincoln

Abstract: Rapid and accurate functional assignment of novel proteins is increasing in importance, given the completion of numerous
genome sequencing projects and the vastly expanding list of unannotated proteins. Traditionally, global primary-sequence and
structure comparisons have been used to determine putative function. These approaches, however, do not emphasize similarities in
active site configurations that are fundamental to a protein’s activity and highly conserved relative to the global and more variable
structural features. The Comparison of Protein Active Site Structures (CPASS) database and software enable the comparison of
experimentally identified ligand-binding sites to infer biological function and aid in drug discovery. The CPASS database comprises
the ligand-defined active sites identified in the protein data bank, where the CPASS program compares these ligand-defined active
sites to determine sequence and structural similarity without maintaining sequence connectivity. CPASS will compare any set of
ligand-defined protein active sites, irrespective of the identity of the bound ligand.
Key words: functional annotation, CPASS, hypothetical proteins, ligand-defined active sites
Grant sponsor: Protein Structure Initiative of the National Institutes of Health; Grant number: P50 GM62413; Grant sponsors: Nebraska
Tobacco Settlement Biomedical Research Development Funds and NASA Nebraska Space Grant and EPSCoR; Grant sponsor: NIH;
Grant number: RR015468-01.

the general observation that tertiary structures are significantly more evolutionary stable than protein sequences.10 Nevertheless, our analyses of the scientific literature for protein structures of hypothetical proteins that are emerging from structural
genomics indicate that ~60% of the reported structures correspond to a novel fold or folds that can not be readily assigned to
a biological function as determined by the authors.
Sequence and structural homology methods primarily determine ‘‘global’’ similarities between the compared proteins.7
However, the molecular function of a protein is generally restricted to its identified active site, which may involve an interaction with small molecular-weight ligands, nucleic acids,
or other proteins. Maintaining the core structural component of
the active site is essential for preserving the functional activity of the protein. As a result, protein comparisons that focus on
global sequence and structural similarities may miss proteins
with conserved active sites but divergent sequences and structures. Thus, a more effective means to infer a biological function of a hypothetical protein would occur through the identification of the protein’s active site.
Comparative analysis of protein active sites is also critical
for a successful drug discovery program, particularly for elim-

Obtaining the biological function of a protein is essential for
determining its potential as a therapeutic target and its utility as
part of structure-based drug design effort. Furthermore, understanding the biological function for a protein provides the basis
for exploring its cellular activity. An outcome of various genomics efforts has been a vast growth in putative protein sequences
that lack any experimental functional annotation.1,2 Sequence
homology has routinely been used as a rapid approach to assign
biological function to these hypothetical proteins or proteins of
unknown function.3 This is based on the accepted structural biology paradigm that a similarity in sequence (≥ 30%) implies a
corresponding similarity in both structure and function. At best,
sequence homology provides functional assignment for ~50%
of the proteins identified in various proteomes.2,4–6 Structural
genomics is augmenting the functional assignment of these hypothetical proteins by determining the corresponding three-dimensional structure.7 This permits a functional assignment by
identifying proteins of known function that exhibit a similar
overall fold to the hypothetical protein. Structural homology
is a more sensitive approach for assigning function, since there
are numerous examples of proteins with similar folds that lack
any significant sequence homology.8,9 This is consistent with
124
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inating potential toxicity pathways. Drug toxicity is a common
cause of failure during clinical trials, where undesirable protein–ligand interactions are a plausible mechanism.11 Efforts to
eliminate potential toxicity problems are initially carried-out by
screening for drug selectivity against a limited panel, for practical reasons, of very closely related proteins.12 These protein
panels are usually composed of functionally identical proteins
with high sequence and structural similarity that are identified
by traditional homology methods. Inevitably, this approach will
miss proteins that only exhibit similarity in the structural characteristics of the active site. This is particularly problematic for
common ligand binding sites, such as ATP, that are drug discovery targets and are present in functionally diverse proteins.13
A number of methodologies are being developed to predict
the location of active sites in novel protein structures. This is
typically accomplished by developing structural descriptors of
active sites for defined protein functional classes and then fitting these structural templates to novel folds to identify putative active sites and annotate the hypothetical proteins. A
variety of approaches are being applied that include aligning
structures to match a few consensus or enzymatic catalytic residues,14–23 identification of cavities consistent with shapes of
known ligands,24 a sequence independent force field to extract
common active site features,25 theoretical prediction of titration curves,26 using chemical properties and electrostatic potentials of amino acid residues consistent with active site characteristics,27,28 neural network analysis of spatial clustering
of residues,29 and conserved residues from multiple sequence
alignments (phylogenetic motifs).20,30
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Nevertheless, direct experimental observation of protein–ligand interactions are a more reliable mechanism for the proper
and accurate identification of protein active sites. LigBase is an
online database that aligns only active sites present in the protein data bank (PDB) that bind the identical ligand, using structure and sequence alignments.31 Similarly, there are numerous
databases that allow searching of the PDB for compounds present in protein–ligand complexes.32–35 Unfortunately, these databases lack the ability to globally compare an active site identified for a novel protein against the entire structural database,
irrespective of the identity of the bound ligand, to determine
the relative similarity in the sequence and structure of the active sites.
Towards this end, we have implemented a database and a
suite of programs to compare experimentally identified protein
active sites to infer biological function (Fig. 1). In this article,
we describe the design and application of the Comparison of
Protein Active Site Structures (CPASS) database and software
that enables both the sequence and structural comparison of ligand-defined active sites to infer functional activity of hypothetical proteins and to aid in the design of drug selectivity.
MATERIALS AND METHODS

Design Philosophy
The main feature that the CPASS program is trying to capture is the similarity in the characteristics of the active site defined by the positions and types of amino acids relative to a

Fig. 1. Schematic diagram of the application of the CPASS database and software to aid in the assignment of biological function to hypothetical
or novel proteins. The bound ligand is colored yellow and the active site residues are colored blue. All molecular images were created using
VMDXPLOR.36
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bound ligand. Unlike other approaches, CPASS does not reduce
the database to a limited collec tion of consensus templates for
each functional family. Similarly, CPASS does not attempt to
simulate generic features of active sites by using descriptors
mimicking important properties of amino acids. Instead, the
CPASS database is composed of ligand-defined protein active
site structures culled from the protein data bank (PDB).
A total of ~34,000 X-ray and NMR structures that are currently available in the PDB were analyzed for the presence of a
bound ligand. The CPASS database is expected to be routinely
updated. Only protein structures that contain a bound ligand are
included in the CPASS database. Conversely, structures that do
not contain a protein molecule, but only contain a DNA or RNA
molecule complexed to a ligand were excluded, since they lack
any value in the functional annotation of a protein. The identification of a ligand within a protein PDB file was determined
by the presence of either a HET or HETNAM record. Routinely, a single protein PDB file may contain multiple ligands. Each
ligand was extracted separately with a uniquely defined active
site in the absence of a LINK record in the PDB file. The LINK
record identifies bonded atoms from two residue types. If a protein PDB file contains multiple ligands with a LINK record that
connects these ligands, then all the ligands are extracted as a
single ligand with a single corresponding active site. As an example, consider a PDB file that contains both ATP and an Mg2+
ion. In the absence of a LINK record that connects the phosphate group from ATP to the Mg2+ ion, two separate ligand coordinate files are extracted—one for ATP and the other for the
Mg2+ ion. The two ligand coordinate files are then used to identify two separate active sites around ATP and the Mg2+ ion, respectively. Conversely, if a LINK record was present in the protein PDB file that indicates a bond between ATP and the Mg2+
ion, a single ligand file is extracted from the protein PDB file
that contains the coordinates for both ATP and Mg2+ ion. This
single file that contains both ligands will then be used to determine a single ligand-based active site.
Besides the presence of small molecular-weight ligands defined by the HET and HETNAM records, a number of protein
PDB structures contain small peptides, DNA, or RNA sequences complexed to the protein. The CPASS database also includes
these small peptides, DNA, and RNA sequences (13 residues)
with the corresponding active site defined by these ligands. The
presence of a peptide or small nucleic acid chain in the protein
PDB file is identified by the SEQRES record, where the total
number of residues for a particular chain is ≤13 and a second
protein chain is defined with >13 residues.
Currently, ~ 42,000 protein–ligand binding sites have been
identified in the PDB. This list excludes common and abundant
buffer reagents, salts, and solvents that generally exhibit nonspecific binding irrelevant to functional activity. A total of 112
ligands are currently excluded from the CPASS database, where
the vast majority are common ions (Na+,Cl–,SO4–), solvents
(water, MES, DMSO, 2-mercaptanol, glycerol), and chemical
fragments or clusters (acetyl, methyl) (see Supplemental Table
1). Practical considerations required removing these ligands because of the significant increase in the total number of ligand-

defined binding-sites in the CPASS database, the negative impact on the CPASS computational time, and the minimal benefit
to functional identification. As an example, the isolated calcium
ion (PDB Het ID: CA) is present in 2887 structures in the PDB,
which results in a total of 7811 binding sites, which by itself
is 30% the size of the entire CPASS library. While it would be
beneficial to include the functionally relevant calcium binding
sites in CPASS, it is not feasible to differentiate between these
sites and the numerous irrelevant calcium binding sites present
in the various structures. Again, simply including all the calcium binding sites is currently impractical, especially when the
7811 binding sites are combined with other similarly excluded ligands. Additionally, numerous X-ray structures contain redundant copies of essentially identical protein–ligand structures
based on the number of structures found within the unit cell.
Multiple binding sites within the same structure are identified
and only one copy is maintained if the ligand-defined active
sites share ≥80% sequence identity and bind the same ligand.
Thus, the list may be reduced to ~26,000 ligand-defined binding sites, when these multiple copies from the same PDB coordinate file are eliminated.
The ligands identified from protein–ligand complexes in the
PDB are then used to determine ligand-defined active sites within the protein structure. The amino acid residues that comprise
an active site are identified by having at least one atom that is
≤ 6Å from any ligand atom. Thus, the ligand chemical structure
and bound conformation determines which amino acids within
the protein comprise the active site. Relative changes in the ligand conformation may result in a corresponding change in the
composition of the ligand-defined active site. The impact on
the active site definition depends on the magnitude of the conformational change and whether this change results in either
the complete loss or gain of an interaction with a specific amino acid. In general, ligand conformational changes have minimal impact on the definition of the residues that describe the
active site, where residues on the 6-Å peripheral are the most
likely to change.
The CPASS active site definition contains the residue types,
the corresponding Cα coordinate positions, and the shortest distance from any atom in the residue to any atom in the ligand (di).
The same active site information is then obtained from a protein–ligand complex for a targeted hypothetical or novel protein
from experimental sources. Sequence and structural similarities of ligand-defined active sites for hypothetical or novel proteins are then compared against the entire PDB derived liganddefined active sites in the CPASS database. Any differences in
ligand conformations between the compared active sites will
have a minimal impact on the calculated similarity, because the
sequence and structure of only the active sites are compared.
The ligand structure is not included in the comparison. Again,
a ligand conformational change may simply result in the addition or exclusion of amino acid(s) residue in the active site definition. Thus, two similar active site sites would not be missed
because of ligand conformation changes, since the remainder
of the residues present in each active site would still exhibit the
expected similarity in sequence and structure.

Comparison of Protein Active Site Structures for Functional Annotation of Proteins and Drug Design

Similarity Function
There are two uniquely critical features of the CPASS analysis of ligand-defined protein active sites to identify similarity in structure and function. First, the CPASS analysis is independent of the identity of the bound ligand. Although CPASS
allows for the comparison of active sites that contain the same
ligand, it is not necessary. The structure of the ligand is not
used in the comparison, since it would eliminate any meaning in aligning active sites with distinct but related ligands. In
this manner, the ligand-defined active site obtained for the target protein can be compared against the entire CPASS database (~26,000 ligand-defined active sites) or any subset of the
database to obtain a meaningful alignment score. Second, the
sequence and structure alignment of the ligand-defined database is not dependent on the primary sequence connectivity of
the protein. In traditional global sequence or structure homology, the primary sequence connectivity is a fundamental component of the alignment analysis, where the insertion of gaps
or deleted regions between the aligned sequences or structures
results in a scoring penalty.37,38 Since the structural organization of a protein active site typically comprises distal sequence
regions of the protein coming into close contact as a result of
the three-dimensional fold, the primary sequence connectivity is not directly relevant to the sequence and structural alignment of an active site.
Thus, the CPASS program determines the optimal sequence and structural alignment between two compared active sites without maintaining sequence connectivity. The
CPASS program determines the alignment of two active sites
by maximizing a root-mean-square-difference (rmsd) weighted
BLOSUM6239,40 scoring function (Sab):

(1)
where active site a contains n residues and is compared with
active site b from the CPASS database, which contains m residues, pi,j is the BLOSUM62 probability for amino acid replacement for residue i from active site a with residue j from
active site b, ∆rmsdi,j is a corrected root-mean-square-difference in the Cα coordinate positions between residues i and j,
and dmin/di is the ratio of the shortest distance to the ligand
among all amino acids in the active site, compared with the
current amino acid’s shortest distance to the ligand. Sab is only
summed over the optimal alignment for residue i from active
site a with residue j from active site b. It is not summed over
all possible combinations of i and j. If the number of residues
are not identical between active sites a and b (n ≠ m), then the
additional residues will not have a corresponding match. Each
residue can be used only once in the alignment. If active site
a contains unmatched residues, then no contribution is made
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to Sab, which effectively reduces the maximal possible score
that can be achieved for active site a. As an example, if active
site a contains an unmatched Ala, a score of 0 is added instead
of a possible maximum score of 4 if active site b contained an
appropriately aligned Ala. The active sites that are being compared are typically in distinct coordinate axes, and so aligning the coordinates in an optimal arrangement without the use
of the primary sequence connectivity requires an iterative approximation guided by maximizing this scoring function.
The BLOSUM62 probability matrix was chosen based
on the reported evaluation of a number of matrixes, where
BLOSUM62 was identified as the best matrix.40 BLOSUM62
is also widely used to construct sequence alignments and is the
default matrix for BLAST.41
The calculated rmsd between residues i and j is corrected by
1 Å (∆rmsdi,j) to account for structural variations less than 1 Å
that are typically within the experimental accuracy of the two
aligned structures. Similarly, squaring the Drmsdi,j weighting function softens the negative impact of larger rmsd values
(>2–5 Å ) and still allows for a positive (nonzero) contribution to the scoring function. These rmsd values are consistent
with generally accepted measures of accuracy for predicted
protein– ligand models and imply a potential functional relevance.42 Thus, a continuous ∆rmsdi,j weighting function is created by simply subtracting 1 Å from the observed rmsd value,
where a negative value is set to zero. So, an observed rmsdi,j of
1.3 Å would result in a ∆rmsdi,j of 0.3 Å and a resulting 0.741
weighting function on the BLOSUM62 probability. Conversely, an observed rmsdi,j < 1.0 Å would result in a ∆rmsdi,j of 0
Å and a resulting 1.0 weighting function on the BLOSUM62
probability.
Since the active site is defined by a strict distance cutoff,
relatively large errors may arise in the alignment score due
to small structural changes that may occur at the active site
boundary. To minimize this effect, the score is also scaled by
the shortest distance from an amino acid in the active site to
the ligand to de-emphasize amino acids that are at the 6-Å
boundary. As an illustration, consider an active site of a targeted protein that contains an alanine where the methyl protons are exactly at the 6-Å limit. The remaining alanine atoms
are all beyond the 6-Å limit. The active site of a reference protein does not include this alanine as part of its active site definition because the alanine methyl protons are 6.1 Å from any
ligand atom and beyond the 6-Å limit. Thus, because of this
0.1-Å change and the corresponding presence and absence of
alanine in the two active site definitions, the similarity scoring
function would decrease by 4.0, when these two active sites
are compared. Assuming the shortest distance from any atom
in the ligand to any atom in the active site is 2 Å , the impact
on the similarity score is reduced to 1.33 by using the dmin/di
(2 Å /6 Å ) scaling. Conversely, the distance scaling also places
more emphasis on active site amino acids that are closer to the
ligand and are presumably more important in both the affinity
and selectivity of the bound ligand.
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Active Site Similarities
The CPASS program generates two outputs: (i) similarity
score and (ii) a file containing the sequence alignment of the
two active sites. The similarity score (S) is simply the ratio of
the scoring function determined by comparing a protein target
active site against a reference active site (Sab) from the CPASS
database, with the scoring function of a protein target active site
compared against itself (Saa).
S = Sab / Saa × 100

(2)

A similarity score is calculated for each comparison. Using the entire CPASS database would result in 26,000 similarity scores. The similarity score is not symmetrical and depends
on the order of the comparison. This arises because the scoring
function is dependent on the size or the number of amino acids
that defines the active site.

Consider comparing a hypothetical or novel protein complexed with adenine against the CPASS database. It is plausible that reference proteins that are complexed with ATP, NAD,
or FAD may exhibit a high similarity based on a near complete
overlap with the adenine component of their ligand-defined active sites with the adenine complexed to the hypothetical protein. The reverse comparison would yield a significantly smaller similarity score, since a single adenine would only represent
a subset of an active site defined by ATP, NAD, or FAD.
To simplify the utility of CPASS and the interpretation of the
CPASS output, a web-based interface has been developed that
will be accessible through our website http://bionmr-c1.unl.edu
(Fig. 2). The CPASS output contains a list of all the aligned active sites, with a similarity score above the cut-off, typically
30%, that is directly linked to a graphical display of the aligned
active sites, using Chime.43,44 Additional information listed is
the sequence alignment, the Cα rmsd-weighted function, the
rmsd-weighted BLOSUM62 scores, and the protein and ligand
identity from the PDB file.

Fig. 2. Screen shots of the web interface to CPASS (a) entry form for active site comparison, (b) list of the active sites with the highest similarity to
target protein, (c) graphical display of the aligned active sites’ structures, sequence alignments, Ca rmsd weighted function, rmsd-weighted BLOSUM62
scores, and information about the aligned protein and its bound ligand. A hyperlink in the similarity list in (b) links to the display in (c).
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RESULTS AND DISCUSSION

Validation of CPASS
The primary application of the CPASS program is to aid in
the functional annotation of hypothetical or novel proteins by
comparing experimentally-defined ligand based active sites.
This is based on the premise that the sequence and structural
composition of a protein active site is uniquely defined by the
biological function of the protein. It is generally accepted that
a global similarity in either sequence or tertiary fold of a protein is correlated to its function.7 The underlying hypothesis in
the application of CPASS is that a biological function may also
be assigned to a protein, based on similarities in the characteristics of experimentally defined ligand based active sites in the
absence of global sequence or structure homology.45
To address this hypothesis and validate the utility of the
CPASS program, a general comparison of active site structures
with known outcomes was conducted. The resolving power of
ligand-defined active sites to identify protein function was ascertained by comparing ATP and pyridoxal 5'-phosphate (PLP)
active sites from a variety of functionally distinct proteins. One
hundred and seventy six ATP binding sites and 294 PLP binding sites were identified from structures in the PDB. The ATP
binding sites were clustered into 19 functional classes based on
the enzyme classification in the BRENDA database.46,47 Similarly, the PLP binding sites were clustered into 20 functional
classes. The ATP binding sites were compared with each oth-
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er for a total of 30,976 comparisons. The PLP binding sites
were compared with each other for a total of 86,436 comparisons. The calculations took ~1–2.5 days on a 16-node Beowulf
Linux cluster, where each comparison averaged ~ 40 s. For each
protein, the best match for each functional class was identified.
Comparisons between proteins with ≥ 95% sequence similarity were excluded from identifying the best match. As an example, a phospho-transferase (PDB ID:1TQP) from Archaeoglobus
fulgidus exhibits the highest similarity (52%) to a phosphotransferase (PDB ID:1PHK) from Oryctolagus cuniculus. Global sequence alignment of 1TQP with 1PHK using ClustalW48 yielded an alignment score of only 8%. Conversely, the best match
of a phosphotransferase to an alkyltransferase (PDB ID:1G64)
is 15%. As anticipated, a higher average similarity score was always seen between proteins of identical function (diagonal) than
functionally distinct proteins (off-diagonal) (Fig. 3). The results
were independent of the type of ligand (ATP, PLP) or protein
function. Nevertheless, the relative range of average similarity scores did vary by the function of the proteins. Comparison
of ATP or PLP binding sites from functionally identical proteins
resulted in relatively high similarity scores (~40–100%). Conversely, functionally distinct proteins generally yielded relatively low similarity scores despite binding the same ligand. Thus,
the highest observed similarity score for a hypothetical protein
determined by comparison against the CPASS database would
identify the protein(s) that has the highest probability of sharing
a similar function with the hypothetical protein.

Fig. 3. A contour plot of the percent similarity determined from the CPASS analysis of (a) 294 pyridoxal 5'-phosphate binding sites and (b)176
ATP binding sites are plotted according to protein function. The diagonal compares proteins of identical function. Contours are plotted in 10%
increments as indicated by the color chart, where the lowest observed contour is 30%.
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Comparison of the ATP and PLP similarity plots (Fig. 3)
clearly indicates a difference in the absolute magnitude of some
of the off-diagonal peaks. A number of the PLP off-diagonal
peaks indicate a 50–60% similarity between different functional classes, whereas the maximum off-diagonal peaks are 30–
40% in the ATP plot. Also, more of the off-diagonal peaks are
>30% in the PLP plot, where a majority of the ATP off-diagonal
peaks are <30%. These observations reflect the relative evolutionary pathways of the ATP and PLP binding sites. Evolutionary analysis of PLP-dependent enzymes indicates only four independent lineages (completely different folds) resulting from
two distinct divergent events (reaction specific, substrate specific) from a primordial PLP protein.49 All PLP-dependent enzymes catalyze amino acid metabolism and as a result share
important mechanistic features that include (i) covalent bond
between PLP and a lysine residue, (ii) amino acid binding site
proximal to PLP for transimination with substrate, (iii) formation of a planer coenzyme-substrate aldimine adduct, and (iv)
optimization of noncovalent interaction between the protein
and the PLP–substrate complex. These mechanistic requirements suggest that PLP caused evolutionary restraints relative
to ATP-dependent proteins. Thus, the evolutionary analysis of
PLP-dependent enzymes that indicates close relationships within this protein family is consistent with the high off-diagonal
similarities observed in the CPASS analysis, using a narrower functional classification. As an example, CPASS indicates
a 63.1% similarity between hydroxymethyl transferase (E.C.
2.1.2) and amino acid acetyl transferase (E.C. 2.3.1), which are
both members of the α-family and closely related in the PLP
phylogenic map.49
Although PLP-dependent enzymes appear to share a common evolutionary pathway, a similar relationship is not expected across the more functionally diverse family of ATP binding
proteins. Clearly, the significant differences in function between actin and kinase proteins would imply a very distinct and
unrelated evolutionary pathway. In fact, identifying an evolutionary relationship between divergent members of the kinase
family alone is challenging.50 These different functional classes
of ATP binding proteins separately and distinctly optimized an
ATP binding site specific to the functional needs of the protein.
Any similarity in the ATP binding site would result from convergent evolution.45,51,52 Again, this lack of a strong evolutionary relationship between the various ATP binding proteins is
consistent with the relatively low off-diagonal similarity scores
observed in the CPASS analysis.
The value of the CPASS analysis is also illustrated by a comparison of the global pair-wise sequence identity determined
by ClustalW48 for the 176 ATP-binding sites with the CPASS
similarity score (Fig. 4). A general linear correlation between
the CPASS and ClustalW alignment scores is expected and observed. Clearly, as the global sequence identity increases, a corresponding increase in the similarity of the active sites would
also occur. This is fundamental to the application of sequence
alignment to assign function. The two circled areas in the graph
indicate regions that significantly deviate from this linearity.

Region (a) corresponds to CPASS similarity scores that are
significantly higher than the corresponding ClustalW scores.
This indicates a high similarity in the sequence and structure
characteristics of active site for proteins with extremely low
(<20%) sequence alignment. These low sequence alignments
are not expected to yield a functional annotation, but are consistent with the observation that numerous homologous proteins
structures exhibit high global sequence diversity.53 Again, by
emphasizing active site structural alignments with an inherently
higher level of conservation relative to global sequence alignments, an increase in the probability of obtaining a functional
annotation can be achieved using CPASS.
Region (b) in Figure 4 corresponds to low CPASS similarity
for proteins with high sequence alignments. Proteins that have
multiple ATP binding sites, which are sequence and structurally distinct, will result in low CPASS scores, when these distinct
active sites are compared. This is an expected result and provides a negative control for validating CPASS. Of course, the
overall sequence similarity would be high, even though the two
ATP binding sites being compared are quite different.
Functional Annotation of Hypothetical Proteins
Further validation of the utility of CPASS to assist in the
functional annotation of hypothetical proteins was ascertained
by analyzing two structures of hypothetical proteins recently
reported in the literature that serendipitously contained a bound
ligand. The 2.0 Å X-ray structure of yeast hypothetical protein
YBL036C contained a covalently attached pyridoxal 5'-phosphate. CPASS comparison against 294 active sites containing
pyridoxal 5'-phosphate indicated that the best match (42% similarity) corresponded to an alanine racemase (Fig. 5).
The function of YBL036C had been tentatively identified
as an alanine racemase.54 Comparison of YBL036C against a
structural database identified alanine racemase and ornithine

Fig. 4. Comparison of the CPASS active site similarity score and
the global percent sequence similarity determined by ClustalW48 for
the 176 ATP binding sites. The circled areas represent significant deviations from a linear relationship between CPASS and ClustalW indicated by the straight line. Region (a) corresponds to high active site
CPASS similarity scores for proteins with low global sequence similarity. Region (b) corresponds to proteins with multiple distinct ATP
binding sites, where CPASS similarity is expected to be low.
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decarboxylase as globally similar in tertiary fold to YBL036C,
where all three proteins exhibit a similar TIM-barrel fold. Nevertheless, a poor alignment of YBL036C against alanine racemase was obtained using the entire TIM-barrel fold. Also, the
structure of YBL036C could not be determined by molecular
replacement using the alanine racemase structure. A brute-force
alignment using a subset of the alanine racemase that included
the PLP active site resulted in a significant improvement with
a 1.72 Å rmsd. Manual comparison of the YBL036C and alanine racemase active sites suggested a significant similarity to
justify testing for D-alanine racemase activity. YBL036C was
shown to exhibit D-to l-alanine racemase activity. Thus, the
CPASS assignment of YBL036C as an alanine racemase is consistent with the previously reported detailed structural and biochemical analysis.
Similarly, a 2.2 Å X-ray structure of hypothetical protein
YecO from Haemophilus influenzae contained a bound S-adenosyl-L-homocysteine and is amenable to CPASS analysis. CPASS
comparison against 46 structures containing S-adenosylmethionine and one structure containing S-adenosyl-L-homocysteine
indicated that the best match (35% similarity) corresponded to
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a glycine N-methyltransferase. This example illustrates the use
of CPASS to compare ligand-defined active sites, using related
but chemically distinct ligand structures. In this case, S-adenosyl-L-homocysteine is a processed cofactor (Fig. 5).
The function of YecO has been identified as a methyl-transferase.55 Again, this was based primarily on structural comparison using DALI56 and VAST,57 along with the presence of S-adenosyl-L-homocysteine. Methlytransferase have extremely low
sequence homology (3–18%), but most methyltransferase bind
the cofactor in a similar manner. Glycine N-methyltransferase
binds S-adenosylmethionine in a drastically different binding
mode, compared with other methyltransferase, and was identified as one of the structures most similar to YecO. Again, the
CPASS assignment of YecO as a methyltransferase is consistent with the previously reported detailed structural analysis.
CPASS identified glycine N-methyltransferase as exhibiting a
similar active site structure as YecO is also consistent with this
previous analysis. These results support the general application of the CPASS database and software to assign a biological
function to novel or hypothetical proteins, by comparing experimentally determined active sites.

Fig. 5. Top: Comparison of the pyridoxal-5'-phosphate defined active sites for (a) yeast hypothetical protein YBL036C (PDB ID:1B54) and
(b) alanine racemase (PDB ID:1RCQ). Bottom: Comparison of the S-adenosyl-L-homocysteine defined active site for (c) hypothetical protein
YecO from Haemophilus influenzae (PDB ID:1IM8) with the (d) S-adenosylmethionine defined active site for glycine N-methyltransferase (PDB
ID:1KIA). The residues aligned by CPASS are colored blue in the structures, and the active site sequence alignments are shown below the
structures. Pyridoxal-5'phosphate, S-adenosyl-L-homocysteine, and S-adenosylmethionine are colored yellow.
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Comparison of CPASS to Other Methods
CPASS shares a similarity in concept to other techniques
that are being developed to infer function for hypothetical proteins.14–19,58 Like CPASS, these approaches are using information about the protein’s active site to make a correlation with a
known protein and assign a function to the unknown protein.
Nevertheless, the application and details of the CPASS approach
are fundamentally distinct from these other methods. For example, the ‘‘Fuzzy Functional Form’’ (FFF) described by Fetrow
and Skolnick59 was developed to provide genome-wide functional annotation, using only the amino acid sequences for each
hypothetical protein. The success of the FFF approach is monitored by the number of correctly annotated proteins instead of
its ability to correctly annotate a specific protein, which is the
objective of CPASS. Thus, the computational speed and broad
coverage requirements of FFF result in significant compromises relative to CPASS that included a simplified and limited active site comparison and the complete absence of experimental data. The three-dimensional protein structure, the identity of
the active site, and protein–ligand complex structures are unknowns in FFF. In fact, the aim of FFF is to predict the structure
and identity of the active site simply from the sequence of the
hypothetical protein and a few structure templates for proteins
of known function.17 This is a very laudable but challenging
goal. Conversely, CPASS depends on the experimentally determined structure and the unambiguous ligand-defined active site
to provide functional information for a single protein.
Briefly, FFF predicts a 3D structure for each hypothetical
protein, by threading the sequence into 2–3 structures for proteins of a specific function.60 Second, FFF uses a consensus active site defined from a sequence alignment of functionally annotated proteins, where an active site residue must be present
in ≥ 50% of the aligned sequences. A functional assignment is
then made if the threaded sequence is consistent with one of the
template structures and if all the conserved active site residues
overlap with the structural template.
Unlike CPASS, only a few highly conserved amino acids are
used to define an active site instead of a complete description
for all the active site residues. Conversely, FFF requires that
the predicted active site for the hypothetical proteins contain an
exact match with the consensus active site, where CPASS provides a similarity score that allows for homologous amino acid
substitution. Again, speed dictates this requirement in FFF, but
the detailed comparison that is achieved by the precise comparison of ~26,000 ligand-defined active sites with CPASS is
lost, potentially resulting in incorrect structural alignments and
false assignments. Consider a simple hypothetical example, if a
consensus active site contains a conserved aliphatic amino acid
(Ala, Ile, Leu, Val), but neither of these residues is consistently
present (≥50%) in the aligned sequences, then FFF will not include this descriptor as part of its active site definition. As a result, a hypothetical protein that contains an Arg at this position
would equally and probably incorrectly match the consensus
active site. There is no differentiation from other hypothetical
proteins that correctly contain this conserved amino acid type.

Conversely, CPASS utilizes each individual active site for the
sequence alignment, where the presence of Arg would result in
a negative impact on the CPASS similarity score.
Furthermore, consider large functional families that contain
hundreds of members, such as kinases and PTPases. Numerous functional subclasses potentially exist within these large
families, where a consensus active site across the entire family
is inappropriate, but accurately delineating membership within the subclasses and correctly defining a consensus active site
for each subclass may be challenging.50 The accuracy of the
functional assignment for FFF is strongly dependent on the correct description of these consensus active sites. These issues are
avoided in CPASS by using the entire ligand-defined active site
for comparison (all the individual kinase, PTPase along with
other protein active sites are used). CPASS specifically identifies which protein-ligand complexes in the CPASS database
and shares a homologous active site with the hypothetical protein. This aspect of CPASS is more computationally intensive
relative to FFF, since it requires a comparison of ~26,000 ligand-defined active sites comprising upwards of ≥ 25 amino acids each. But, the structural threading is similarly computationally expensive in the FFF protocol requiring a limited number
of structural templates.
Other approaches similar to FFF also attempt to predict function or identify active sites through the use of homology models based on known protein structures.18,19 These models generally suffer from an abundance of false positives because of
the accuracy of the threading procedure. An accurate threaded
structure requires 60% of residues in the hypothetical sequence
to occupy structurally analogous sites in the target structure.61
Thus, the sequence for the hypothetical protein needs to share
more than 50% sequence identity with the protein structure
template.62 Nevertheless, any sequence can be threaded into a
structure template and simply evaluated by an empirical energy function, resulting in incorrect predicted folds. CPASS does
not attempt to predict a structure for a hypothetical protein but
requires the availability of this structure and avoids the uncertainty generated by a predicted structure. Effectively, FFF and
other similar programs are analogous to global sequence alignments, but utilize a structural homology filter to refine the global sequence alignment.
Application of CPASS in Drug Discovery
An important issue in drug discovery is designing selectivity
into chemical leads to avoid undesirable activity that may cause
toxic side-effects in clinical trials.63 Improving the affinity of
a chemical lead against a defined protein target can be readily quantified, but determining the relative selectivity against all
potential targets is impractical. The main challenge is in identifying proteins that may be inadvertent targets of the chemical
lead. Again, global sequence or structural homology to the protein target is the major method of identifying proteins with a potential affinity to the chemical lead. Unfortunately, this does not
yield a thorough analysis of the proteome or a prediction of ligand affinity, since the comparison is not specific to the active
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site. CPASS provides an additional approach to identifying potential cross-reactivity between proteins of diverse function by
identifying related ligand-biding sites. The ATP and PLP binding-site analysis indicates that the highest observed similarity
is between proteins of identical function (Fig. 3). Nevertheless,
there are a number of examples where functionally distinct proteins share >30–40% similarity (off-diagonal), such as ATPases
and cell division proteins for the ATP binding proteins and hydrolyase and ammonia-lyase for the PLP-dependent enzymes.
Again, CPASS will not provide a complete analysis of the entire proteome, since it is limited to the representative protein
structures and functions in the PDB. But, CPASS will assist in
improving the selectivity of chemical leads by expanding the
list of relevant proteins beyond those proteins that are functionally related to the target. Thus, CPASS can identify a broader
spectrum of proteins to use in biological assays to test for activity and selectivity against potential drug candidates.
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Table 1S: List of Ligands and PDB HET Labels Excluded from the CPASS Database
2-mercaptanol
acetate
acetic acid
acetone
acetonitrile

BME, SEO
ACT
ACY
ACN
CCN

lanthanum
lead
lithium
lutetium
magnesium

alcohol

IPA

manganese

aluminum
amide
antimony
argon
arsenic
azide

AL
AF3,NH2,NH4,NH3, NH
SBO, ND4
SB
ARS, AST, AR
AZI

mercury
methanol
methylamine
methyl phosphinic acid
MES
molybdenum

barium
beryllium
bicarbonate
borate
boric acid
bromine
bromomercury
cacodylate
cadmium

BA
BEF, BF2, BF4
BCT
BO4
BO3
BR, BRO
HG2
CAC
CD, CD1, CD3, CD5

nickel
nickel-iron
nitogen dioxide
nitrate
nitrite
nitrogen monoxide
nitrogen oxide
osmium
oxygen

calcium

CA, OC1, OC2, OC3, OC4,
OC5, OC6, OC7, 543
CO2
CMO
CE

palladium

carbon dioxide
carbon monoxide
cerium
cesium
chlorine
cobalt
copper
copper chloride
copper-sulfer cluster
cyanide
dimethylformamide
DMSO
ethanol
ethylene glycol

CS
CL, CLO, CFO, LCO
CO, 3CO, NCO, OCL, OCN,
OCM, CO5, OCO, CON
CU, CU1, ICU, CUO, C2C,
C1O, C2O, CUA, CUZ
CUL
CUN, CUM
CN, CYN
DMF
DMS
EOH
EDO, EGL

perchlorate
peroxide
phosphate

LA
PB, PBM
LI
LU
MG, MO1, MO2, MO3,
MO4, MO5, MO6
MN, MN3, MN5,
MW1, MW2, MW3,
MH2, MH3, O4M
HG, HG1
MOH
NME
SOM
MES
MOS, MO7, OMO,
MOO, MM4, MO,
4MO, 6MO
NI, 3NI, NI1, NI2
NFE
2NO
NO3
NO2
NMO
NO
OS
O, OX, OEC, O2,
OXY, HF5
PD

phosphite
platinum
porphyrin

LCP
PEO, PER
2HP, DPO, FPO, PI,
IPS, PO4, 3PO
PO3
PCL
HCO

potassium

K, KO4

praseodymium
rhenium
rhodium
rithenium
rubidium
samarium
selenium

PR
RE, RTC
RHD
RU
RB
SM
SE4, SE, MSE

europium
fluorine

EU, EU3
F, FLO

silver
sodium

formic acid
gadolinium
galluim
glucosamine
glycerol
gold
holimium
hydrogen
hydrosulfuric acid
hydroxy
hypophosphite
indium
iodine
iridium

FMT
GD, GD3
GA
NAG
GOL
AU, AU3, AUC
HO
H
H2S
OH, HYD
PO2
IN
IOD, IDO
IR, IR3, IRI

strontium
sulfate
sulfite
sulfur
sulfur dioxide
sulfur oxide
tantalum
tellerium
terbium
thallium
tungsten
uranyl
vanadium
water

iron

OF2, HC1, FCO, FE, FE2,
xenon
OF3, OF1, 2OF, FEL, OFO,
FEA, FEO
WCC, XCC, NFS, CFM, CFN, ytterbium
YB
CLP, FES, F3S, FS3, FS4,
SF4, FSO
KR
yttrium
YT3, Y1
NAG
zinc
ZN, ZN2, ZN3,
ACE, BUT, CBZ, CO3, CBX, CBM, CM, MCE, CBG, DTN, ETD, ETH, OET, EMC,
EOX, FOR, HOA, OHE, OME, 2ME, CH3, TML, MCB, CH2, HDZ, TFH, WO2,
OXO, ZRC, CNB, CN1, CNF, OXA, QTR, CYO, OMB, 2PO, PHS, PPM, PVL,
SBU, HF3, SFO, SFN, DML, TBU, NTB, ALF, TMA, THJ, SCN, SCC, TFA, MGF,
TME, CYA, UNX, UNK, UNL, U1, DIS

iron-sulfur cluster

krypton
glucosamine
various small molecular
fragments or clusters

AG
NA, NAW, NAO, NA2,
NA5, NA6
SR
SOH, SUL
SO3
S
SO2
SX
TBR
TE
TB
TL
W, WO4, WO5
IUM
V, V7O, VO3, VO4
MTO, DOD, HOH,
WAT
XE

